文献速递重症综合管理与镇静镇痛心脑血管急症

基于个体化连接组图谱指导靶向治疗并促进ICU意识恢复

Personalized Connectome Mapping to Guide Targeted Therapy and Promote Recovery of Consciousness in the Intensive Care Unit.
PubMed 文献 · Neurocrit Care · 2020-08-13
一句话结论STIMPACT 试验方案:对急性重型创伤性脑损伤所致意识障碍患者,按个体化连接组图谱靶向使用静脉哌甲酯促进意识恢复,1期开放标签剂量探索(0.5-2.0 mg/kg,4天)。

目前尚无疗法被证实能在ICU促进重型脑损伤患者的早期意识恢复。本文提出基于连接组的临床试验平台(CCTP),并报告基于该平台的STIMPACT试验方案:对急性重型创伤性脑损伤所致意识障碍患者,静脉使用哌甲酯靶向刺激皮层下上行觉醒网络内的多巴胺能环路(NCT03814356)。1期为开放标签安全性及剂量探索研究,纳入22例,在4天内逐步递增每日剂量0.5-2.0 mg/kg,并进行静息态功能磁共振与脑电图评估药效学。1期主要结局为安全性(各剂量药物相关不良事件数),次要结局包括达峰时间、血清半衰期、最高耐受剂量对静息态功能磁共振连接生物标志物的影响及各剂量对脑电皮层功能生物标志物的影响;1期须满足预设安全性和药效学标准方可进入2A期。

要点

  • 目前尚无疗法被证实能在ICU促进重型脑损伤患者的早期意识恢复,这是该方案提出的背景。
  • STIMPACT的1期为开放标签、安全性和剂量探索研究,纳入22例急性重型创伤性脑损伤所致意识障碍患者。
  • 1期给药方案为静脉哌甲酯每日剂量递增0.5-2.0 mg/kg,疗程4天。
  • 1期主要结局是安全性:各剂量下药物相关不良事件的数量。
  • 1期须满足预设安全性和药效学标准才能推进至2A期;2A期将检验个体化连接组图谱预测静脉哌甲酯治疗反应的假设。

适用人群与场景

  • 1期人群:急性重型创伤性脑损伤所致意识障碍患者,共22例。
  • 2A期:检验个体化连接组图谱预测静脉哌甲酯治疗反应的假设;2B期计划按个体化连接组图谱纳入患者。

诊断标准与关键阈值

  • 推进标准:1期须满足预设的安全性和药效学标准方可进入2A期。

处置流程与药物剂量

  • 1期给药:静脉哌甲酯每日剂量递增0.5-2.0 mg/kg,疗程4天。
  • 1期同步评估:静息态功能磁共振和脑电图,用于评价药物的药效学特性。

研究设计与关键结果

  • 研究类型:CCTP平台下STIMPACT试验的方案报告;1期为开放标签、安全性和剂量探索研究,纳入22例急性重型创伤性脑损伤所致意识障碍患者。
  • 1期主要结局:安全性,即各剂量下药物相关不良事件的数量。
  • 1期次要结局:(1)达最大血清浓度时间;(2)血清半衰期;(3)最高耐受剂量对静息态功能磁共振连接生物标志物的影响;(4)各剂量对脑电皮层功能生物标志物的影响。
  • 1期药代动力学数据将用于指导2A期研究设计;2A期结果将用于指导2B期设计(计划按个体化连接组图谱纳入患者)。

证据类型、等级与局限

  • 证据类型:试验方案报告(STIMPACT,ClinicalTrials.gov NCT03814356),1期为开放标签、安全性和剂量探索研究。
  • 1期主要关注安全性(各剂量药物相关不良事件数),尚待1期预设安全性和药效学标准满足后方可推进至2A期。

对床旁实践的改变

  • 作者提出CCTP范式,认为在ICU进行个体化脑网络图谱可识别连接组适合神经调控的患者,从而按神经解剖学治疗反应潜力选择临床试验人群。
  • 作者认为该范式与STIMPACT试验有潜力改变ICU治疗格局并改善重型脑损伤患者结局。
  • 目前尚无疗法被证实能在ICU促进重型脑损伤患者的早期意识恢复;静脉哌甲酯0.5-2.0 mg/kg、4天的方案为1期试验方案,非通用推荐。

指南或共识出处

  • STIMPACT试验方案(ClinicalTrials.gov NCT03814356)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

There are currently no therapies proven to promote early recovery of consciousness in patients with severe brain injuries in the intensive care unit (ICU). For patients whose families face time-sensitive, life-or-death decisions, treatments that promote recovery of consciousness are needed to reduce the likelihood of premature withdrawal of life-sustaining therapy, facilitate autonomous self-expression, and increase access to rehabilitative care. Here, we present the Connectome-based Clinical Trial Platform (CCTP), a new paradigm for developing and testing targeted therapies that promote early recovery of consciousness in the ICU. We report the protocol for STIMPACT (Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness), a CCTP-based trial in which intravenous methylphenidate will be used for targeted stimulation of dopaminergic circuits within the subcortical ascending arousal network (ClinicalTrials.gov NCT03814356). The scientific premise of the CCTP and the STIMPACT trial is that personalized brain network mapping in the ICU can identify patients whose connectomes are amenable to neuromodulation. Phase 1 of the STIMPACT trial is an open-label, safety and dose-finding study in 22 patients with disorders of consciousness caused by acute severe traumatic brain injury. Patients in Phase 1 will receive escalating daily doses (0.5-2.0 mg/kg) of intravenous methylphenidate over a 4-day period and will undergo resting-state functional magnetic resonance imaging and electroencephalography to evaluate the drug's pharmacodynamic properties. The primary outcome measure for Phase 1 relates to safety: the number of drug-related adverse events at each dose. Secondary outcome measures pertain to pharmacokinetics and pharmacodynamics: (1) time to maximal serum concentration; (2) serum half-life; (3) effect of the highest tolerated dose on resting-state functional MRI biomarkers of connectivity; and (4) effect of each dose on EEG biomarkers of cerebral cortical function. Predetermined safety and pharmacodynamic criteria must be fulfilled in Phase 1 to proceed to Phase 2A. Pharmacokinetic data from Phase 1 will also inform the study design of Phase 2A, where we will test the hypothesis that personalized connectome maps predict therapeutic responses to intravenous methylphenidate. Likewise, findings from Phase 2A will inform the design of Phase 2B, where we plan to enroll patients based on their personalized connectome maps. By selecting patients for clinical trials based on a principled, mechanistic assessment of their neuroanatomic potential for a therapeutic response, the CCTP paradigm and the STIMPACT trial have the potential to transform the therapeutic landscape in the ICU and improve outcomes for patients with severe brain injuries.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Edlow BL, Barra ME, Zhou DW, et al. Personalized Connectome Mapping to Guide Targeted Therapy and Promote Recovery of Consciousness in the Intensive Care Unit. Neurocrit Care. 2020. PMID: 32794142. doi:10.1007/s12028-020-01062-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。